Genmab: Enrollment complete in rheumatoid arthritis study

By Lisa Kerner

Charlotte, N.C., Sept. 22 - Enrollment is complete in Genmab A/S' HuMax-CD20 (ofatumumab) phase 2 study to treat patients with active rheumatoid arthritis.

Approximately 200 rheumatoid arthritis patients who have failed treatment with one or more disease modifying anti-rheumatic drugs will participate in the study, according to the Copenhagen, Denmark, biotechnology company.

HuMax-CD20 is also being studied as a treatment for chronic lymphocytic leukemia and follicular non-Hodgkin's lymphoma.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.